Cardiff Oncology to Announce Q2 2024 Results and Business Update

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, is pioneering the use of PLK1 inhibition to develop innovative cancer therapies. Cardiff Oncology has announced plans to disclose its financial results for the second quarter, which ended on June 30, 2024. The announcement is scheduled for release on Thursday, August 8, following the closure of trading on that day.

The company will also host a conference call and live webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT. Those interested in joining the live call can access it through the webcast link available in the "Investors" section of Cardiff Oncology's website. Furthermore, a replay will be accessible in the investor relations section on the company's official website after the call concludes.

Cardiff Oncology focuses on leveraging PLK1 inhibition, a validated target in oncology, to create new treatment options for various cancers. The company's primary asset, onvansertib, is a PLK1 inhibitor. This drug is currently being tested in combination with standard-of-care (SoC) therapies in clinical trials targeting conditions such as RAS-mutated metastatic colorectal cancer (mCRC). Additionally, onvansertib is also being evaluated in investigator-initiated trials for metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).

The company's development programs aim to exploit tumor vulnerabilities, thereby overcoming treatment resistance and providing superior clinical benefits compared to SoC alone. This strategy underscores Cardiff Oncology's commitment to advancing cancer treatment by targeting specific tumor characteristics.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!